Trial Profile
A phase I/II proof-of-concept study of Systebryl (PTI-110) in AL amyloidosis patients
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 15 Jan 2015
Price :
$35
*
At a glance
- Drugs PTI 110 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 15 Jan 2015 New trial record